EGFR and non-small cell lung carcinoma: Approximately half or more NSCLC patients with EGFR mutations who develop resistance to the first- and second-generation EGFR-tyrosine kinase inhibitors (TKI) will develop a secondary EGFR T790M mutation in the tumor (61).